Clinical trials: Ejection Fraction
Heart Failure With Preserved Ejection Fraction
Study of Sacubitril/ValsarTan on MyocardIal OxygenatioN and Fibrosis in Heart Failure With Preserved Ejection Fraction
To assess the effect of ARNI on myocardial deoxygenation at stress and myocardial fibrosis, and correlate this to changes in myocardial systolic and diastolic function in HFpEF patients.
- Trial name
- PRISTINE-HF (NCT04128891)
- Testing
- Sacubitril-Valsartan
- Sponsor
- Flinders University
Chronic Heart Failure With Reduced Ejection Fraction
A Study to Assess the Safety, Tolerability and Efficacy of IONIS-AGT-LRx in Participants With Chronic Heart Failure With Reduced Ejection Fraction
The purpose of this study is to evaluate the effect of IONIS-AGT-LRX weekly subcutaneous (SC) injection on plasma angiotensinogen (AGT) concentration from Baseline to Study Day 85 (Week 13) and to evaluate the effect of…
- Trial name
- ASTRAAS-HF (NCT04836182)
- Testing
- IONIS-AGT-LRx
- Where
- 19 sites in United States, Hungary and 1 more
- Volunteers
- 72 people
- Sponsor
- Ionis Pharmaceuticals, Inc.
Heart Failure With Reduced Ejection Fraction
Lumacaftor Yields Reversal of Impaired Cerebral Blood Flow in Heart Failure Patients
Cognitive impairment (CI) is highly prevalent in patients with heart failure with reduced ejection fraction (HFrEF), which has significant implications for disease management, quality of life and clinical outcomes.
- Trial name
- LYRIC-HF (NCT07695090)
- Testing
- Lumacaftor 200 MG
- Where
- 2 sites in Canada
- Volunteers
- 60 people
- Sponsor
- Qanatpharma AG
Heart Failure With Reduced Ejection Fraction
Hemodynamic Effects of ARNI on Noninvasive Pressure-volume Analysis in Patients With Chronic Heart Failure
Sacubitril-Valsartan reduced heart failure hospitalizations and cardiovascular mortality compared to enelapril in chronic heart failure. Furthermore, quality of life is improved.
- Trial name
- ARNI-PVA (NCT04498780)
- Testing
- Sacubitril-Valsartan
- Where
- 2 sites in Germany
- Volunteers
- 117 people
- Sponsor
- University of Leipzig
Heart Failure With Reduced Ejection Fraction (HFrEF), Heart Failure
Real-world Effectiveness and Safety of Savagen (Sacubitril/Valsartan) in Malaysian HFrEF Patients
This multicentre, prospective, single-arm cohort study will evaluate the real-world effectiveness and safety of Savagen, an NPRA-approved generic sacubitril/valsartan, in Malaysian adults aged 18 to 70 years with heart failure…
- Trial name
- NCT07907640
- Testing
- Savagen (sacubitril/valsartan)
- Where
- 2 sites in Malaysia
- Volunteers
- 80 people
- Sponsor
- Sunway University
Myocardial Infarction, Sudden Death
Clinical Registry on Sudden Death Primary Prevention at Latin America
INTRODUCTION: Sudden cardiac death is one of the most important reasons of death at industrialized countries. Despite its importance, nowadays Clinical Guidelines are not as extended as expected, with respect to indications for…
- Trial name
- ESCAPE-ICD (NCT01422174)
- Testing
- Implantable Cardio Defibrillator (ICD),
- Where
- Argentina
- Sponsor
- Biotronik SE & Co. KG
Heart Failure, Reduced Ejection Fraction Heart Failure
Sodium-glucose Transport 2 Inhibitors (SGLT2i) in HFrEF Patients
The aim of this study is to assess the efficacy, safety and cardiovascular outcomes of Sodium-glucose transport protein 2 inhibitors (SGLT2i) therapy in patients with heart failure reduced ejection fraction ( HFrEF) with and…
- Trial name
- NCT06065280
- Testing
- Empagliflozin 10 MG, Dapagliflozin 10 MG
- Where
- Egypt
- Volunteers
- 80 people
- Sponsor
- Damanhour University
Heart Failure
Biventricular Epicardial Pacing Post Cardiac Surgery in Patients With Left Ventricular Ejection Fractions Less Than 45%
Patients with reduced left ventricular function are at an increased perioperative risk and often need prolonged postoperative treatment on intensive care units.
- Trial name
- NCT00604110
- Testing
- Biventricular pacing post cardiac surgery
- Where
- France
- Volunteers
- 12 people
- Sponsor
- University Hospital, Clermont-Ferrand
Atrial Fibrillation, SGLT2 Inhibitor
Clinical Impact of SGLT2 Inhibitor After DC Cardioversion in Persistent AF With HFpEF
SGLT2 inhibitors improve outcomes in heart failure across the ejection fraction spectrum, but their effect on maintenance of sinus rhythm after rhythm-control therapy is largely unknown.
- Conditions
- Atrial Fibrillation, SGLT2 Inhibitor, DC Cardioversion
- Trial name
- NCT07776054
- Testing
- SGLT2 inhibitors (Dapagliflozin and Empagliflozin)
- Where
- South Korea
- Volunteers
- 200 people
- Sponsor
- Samsung Medical Center
Heart Failure, Heart Failure, Diastolic
Data-Driven Phenotyping in Heart Failure With Preserved Ejection Fraction
The goal of this observational study is to learn how people with Heart Failure with Preserved Ejection Fraction (HFpEF) can be grouped into different "phenotypes" based on their clinical information.
- Conditions
- Heart Failure, Heart Failure, Diastolic, Heart Failure With Preserved Ejection Fraction (HFPEF)
- Trial name
- NCT07429396
- Where
- 2 sites in Portugal
- Volunteers
- 200 people
- Sponsor
- Instituto Politécnico de Leiria
Heart Failure With Reduced Ejection Fraction (HFrEF), Sacubitril/Valsartan
Evaluating Dashboard-Integrated Pharmacist-Led Education on Improving Sacubitril/Valsartan Adherence in Heart Failure (PharmD ASSIST HFrEF)
The goal of this pragmatic clinical trial is to evaluate whether pharmacist-led education, integrated with interactive visualization dashboards, can enhance medication adherence in patients with heart failure who are prescribed…
- Conditions
- Heart Failure With Reduced Ejection Fraction (HFrEF), Sacubitril/Valsartan, Medication Adherence
- Trial name
- NCT06900803
- Testing
- interactive visualization dashboard (the Enhancing Sacubitril/valsartan Adherence from Initiation to Continuation [ESAIC] dashboard)
- Volunteers
- 200 people
- Sponsor
- National Taiwan University Hospital
Heart Failure With Reduced Ejection Fraction, Obesity
Effect of Weight Loss on Physical and Cardiac Performance in People With Obesity and Heart Failure
The benefit of weight loss in patients with obesity and heart failure with reduced ejection fraction (HFrEF) is controversial. Semaglutide has shown cardiovascular (CV) risk-reduction and impact on CV risk factors including…
- Conditions
- Heart Failure With Reduced Ejection Fraction, Obesity, Weight Loss, Chronic Heart Failure
- Trial name
- FIT-HF (NCT06423599)
- Testing
- Semaglutide Injectable Product, Calorie-restricted diet
- Where
- Denmark
- Volunteers
- 100 people
- Sponsor
- Jens D Hove, MD,PHD
Cardiac Failure, Systolic Heart Failure
Ferric Carboximaltose on Intra-myocardial Iron Load in Patients With Heart Failure
In general, anemia is associated with a greater presence of HF symptoms, worsening NYHA functional class, higher rate of hospitalization for heart failure, and reduced survival.
- Conditions
- Cardiac Failure, Systolic Heart Failure, Heart Failure, Systolic
- Trial name
- IronHeart (NCT03871699)
- Testing
- Ferric carboxymaltose
- Where
- Brazil
- Volunteers
- 20 people
- Sponsor
- Hospital Moinhos de Vento
Coronary Artery Disease, Unstable Angina
Restore EF Observational Study
A multi-center, prospective, observational, non-interventional single arm, study of the intermediate-term clinical outcomes collected from electronic health records of high-risk patients which have previously undergone standard…
- Conditions
- Coronary Artery Disease, Unstable Angina, Angina, Stable, NSTEMI - Non-ST Segment Elevation MI
- Trial name
- NCT04648306
- Testing
- Prophylactic Impella support for a non-emergent PCI
- Where
- 21 sites in United States
- Volunteers
- 406 people
- Sponsor
- Abiomed Inc.
Atrial Fibrillation Paroxysmal, Coronary Artery Disease Without Residual Ischemia
Flecainide Versus Amiodarone in the Cardioversion of Paroxysmal Atrial Fibrillation at the Emergency Department, in Patients With Coronary Artery Disease Without Residual Ischemia
Current guidelines for the cardioversion of paroxysmal Atrial Fibrillation at the Emergency Department do not prioritize between antiarrhythmic agents and do not consider the time taken for successful cardioversion.
- Trial name
- FLECA-ED (NCT05549752)
- Testing
- Flecainide Injectable Solution, Amiodarone Injectable Solution
- Where
- 3 sites in Greece
- Volunteers
- 80 people
- Sponsor
- Hippocration General Hospital
Heart Failure, Diagnosis
Heart Failure With Improved Ejection Fraction and Deep Learning
The aim of this study was to design a deep learning-based trained model to assist in HFimpEF diagnosis.
- Trial name
- NCT06070506
- Where
- China
- Volunteers
- 422 people
- Sponsor
- Yihui Kong
Left Ventricular Dysfunction
Use of Adult Autologous Stem Cells in Treating People Who Have Had a Heart Attack (The TIME Study)
Heart attacks are a leading cause of death for both men and women in the United States. A heart attack occurs when blood flow to the heart is restricted, commonly due to a blood clot that has formed in one of the coronary…
- Trial name
- NCT00684021
- Testing
- Adult stem cells
- Where
- 5 sites in United States
- Volunteers
- 120 people
- Sponsor
- The University of Texas Health Science Center, Houston
Heart Failure With Preserved Ejection Fraction (HFpEF)
Ventricular Tachyarrhythmia Detection by Implantable Loop Recording in Patients With Heart Failure and Preserved Ejection Fraction
Heart failure with preserved ejection fraction (HFPEF) is a large medical problem, for which no drug or device has a recommendation in current heart failure guidelines.
- Trial name
- VIP-HF (NCT01989299)
- Testing
- ILR implantation
- Where
- 5 sites in Netherlands
- Volunteers
- 113 people
- Sponsor
- University Medical Center Groningen
Physical Activity, Heart Failure
WHISH-2-Prevent Heart Failure
The WHISH-2-Prevent Heart Failure (HF) study is an ancillary study to the Women's Health Initiative Strong and Healthy (WHISH) exercise pragmatic trial.
- Conditions
- Physical Activity, Heart Failure, Heart Failure With Reduced Ejection Fraction, Heart Failure With Normal Ejection Fraction
- Trial name
- NCT03099889
- Testing
- Physical Activity
- Where
- United States
- Volunteers
- 49,936 people, healthy volunteers welcome
- Sponsor
- Memorial Hospital of Rhode Island
Heart Failure
REDUCE LAP-HFREF TRIAL
The objective of this pilot study is to evaluate the safety and performance of implanting the IASD® System II in Heart Failure patients with reduced ejection fraction and elevated left sided filling pressures, who remain…
- Trial name
- NCT03093961
- Testing
- IASD implant
- Where
- 4 sites in United States, Australia and 1 more
- Volunteers
- 10 people
- Sponsor
- Corvia Medical
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.